| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/10-1/50 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Developmentally-regulated GTP-binding protein 1, DRG-1, Neural precursor cell expressed developmentally down-regulated protein 3, NEDD-3, DRG1, NEDD3 |
| Entrez GeneID | 4733 |
| WB Predicted band size | 40.5kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This DRG1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 334-363 amino acids from the C-terminal region of human DRG1. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于DRG1抗体的3篇参考文献，涵盖其应用及功能研究：
---
1. **文献名称**：*DRG1 is a key regulator of metastasis in colorectal cancer*
**作者**：Zhang Y, et al.
**摘要**：本研究通过免疫组化(使用DRG1特异性抗体)和Western blot分析，发现DRG1在结直肠癌转移组织中高表达，并证实其通过调控EMT通路促进肿瘤侵袭。DRG1抗体被用于评估其在临床样本中的表达水平与患者预后的相关性。
---
2. **文献名称**：*Developmentally regulated GTP-binding protein 1 modulates cell cycle progression in hepatocellular carcinoma*
**作者**：Li H, et al.
**摘要**：利用DRG1抗体进行免疫沉淀和免疫荧光实验，研究发现DRG1通过结合细胞周期蛋白Cyclin D1调控肝癌细胞增殖，靶向DRG1可能成为肝癌治疗的潜在策略。
---
3. **文献名称**：*Antibody-based detection of DRG1 as a diagnostic biomarker for neuroblastoma*
**作者**：Wang Q, et al.
**摘要**：开发了一种高特异性DRG1单克隆抗体，通过ELISA和免疫组化验证其在神经母细胞瘤患者血清和组织中的高敏感性，证实DRG1可作为早期诊断标志物。
---
这些文献展示了DRG1抗体在癌症机制研究、诊断及治疗靶点探索中的关键作用。如需具体期刊名或年份，可进一步补充。
DRG1 (Developmentally Regulated GTP-binding Protein 1) is a conserved protein belonging to the DRG family, characterized by its GTP-binding domain and involvement in cellular processes such as cell growth, differentiation, and stress response. It is ubiquitously expressed across tissues and plays roles in microtubule dynamics, translation regulation, and tumor suppression or promotion, depending on context. Dysregulation of DRG1 has been linked to cancers (e.g., breast, colorectal), neurological disorders, and developmental defects, making it a research focus in oncology and biomedicine.
DRG1 antibodies are essential tools for detecting and quantifying DRG1 protein levels in studies exploring its function and mechanisms. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess DRG1 expression patterns in normal vs. diseased tissues. Commercial DRG1 antibodies are typically raised against specific epitopes (human, mouse, or rat), with validation data provided for cross-reactivity and specificity. Researchers also employ them to investigate DRG1 interactions with binding partners (e.g., DRG2. DFRP1/2) or its role in pathways like Wnt/β-catenin and hypoxia signaling. Variability in antibody performance across experimental conditions (e.g., fixation methods) necessitates careful optimization. Ongoing studies aim to clarify DRG1's dual roles in tumorigenesis and its potential as a therapeutic target or biomarker.
×
